Zoetis Inc. (NYSE:ZTS) Shares Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its stake in Zoetis Inc. (NYSE:ZTS) by 1.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 54,000 shares of the company’s stock after buying an additional 509 shares during the period. Oppenheimer & Co. Inc.’s holdings in Zoetis were worth $10,551,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. OLD Second National Bank of Aurora boosted its stake in Zoetis by 0.7% in the third quarter. OLD Second National Bank of Aurora now owns 11,684 shares of the company’s stock valued at $2,283,000 after acquiring an additional 81 shares in the last quarter. Pinnacle Financial Partners Inc lifted its holdings in shares of Zoetis by 5.2% in the 3rd quarter. Pinnacle Financial Partners Inc now owns 45,865 shares of the company’s stock valued at $8,961,000 after purchasing an additional 2,264 shares during the last quarter. Haverford Trust Co boosted its position in shares of Zoetis by 0.4% in the 3rd quarter. Haverford Trust Co now owns 130,210 shares of the company’s stock valued at $25,440,000 after purchasing an additional 495 shares during the period. Victory Capital Management Inc. boosted its position in shares of Zoetis by 8.6% in the 3rd quarter. Victory Capital Management Inc. now owns 338,866 shares of the company’s stock valued at $66,208,000 after purchasing an additional 26,789 shares during the period. Finally, Aptus Capital Advisors LLC grew its stake in Zoetis by 2.2% during the 3rd quarter. Aptus Capital Advisors LLC now owns 4,532 shares of the company’s stock worth $885,000 after buying an additional 97 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 1.9 %

NYSE ZTS opened at $177.28 on Thursday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $79.98 billion, a P/E ratio of 33.32, a P/E/G ratio of 2.67 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The firm has a 50-day moving average price of $187.81 and a 200 day moving average price of $180.04.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the business posted $1.36 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities research analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.97%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Analysts Set New Price Targets

ZTS has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus upped their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.